nodes	percent_of_prediction	percent_of_DWPC	metapath
Trabectedin—CYP3A4—bone cancer	0.718	1	CbGaD
Trabectedin—Febrile neutropenia—Methotrexate—bone cancer	0.00143	0.00866	CcSEcCtD
Trabectedin—Skin hyperpigmentation—Epirubicin—bone cancer	0.00135	0.0082	CcSEcCtD
Trabectedin—Mucosal inflammation—Doxorubicin—bone cancer	0.00135	0.00815	CcSEcCtD
Trabectedin—Febrile neutropenia—Epirubicin—bone cancer	0.00134	0.00811	CcSEcCtD
Trabectedin—Skin hyperpigmentation—Doxorubicin—bone cancer	0.00125	0.00759	CcSEcCtD
Trabectedin—Febrile neutropenia—Doxorubicin—bone cancer	0.00124	0.0075	CcSEcCtD
Trabectedin—Hepatomegaly—Epirubicin—bone cancer	0.00114	0.00689	CcSEcCtD
Trabectedin—Hepatotoxicity—Methotrexate—bone cancer	0.00111	0.00675	CcSEcCtD
Trabectedin—Necrosis—Methotrexate—bone cancer	0.0011	0.00664	CcSEcCtD
Trabectedin—Blood creatinine increased—Cisplatin—bone cancer	0.00107	0.00646	CcSEcCtD
Trabectedin—Dehydration—Cisplatin—bone cancer	0.00106	0.00641	CcSEcCtD
Trabectedin—Hepatomegaly—Doxorubicin—bone cancer	0.00105	0.00637	CcSEcCtD
Trabectedin—Hypokalaemia—Cisplatin—bone cancer	0.00104	0.00627	CcSEcCtD
Trabectedin—Necrosis—Epirubicin—bone cancer	0.00103	0.00621	CcSEcCtD
Trabectedin—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.00103	0.00621	CcSEcCtD
Trabectedin—Extravasation—Methotrexate—bone cancer	0.000986	0.00597	CcSEcCtD
Trabectedin—Liver injury—Epirubicin—bone cancer	0.000957	0.0058	CcSEcCtD
Trabectedin—Necrosis—Doxorubicin—bone cancer	0.000949	0.00575	CcSEcCtD
Trabectedin—Hyperbilirubinaemia—Methotrexate—bone cancer	0.000946	0.00573	CcSEcCtD
Trabectedin—Pancytopenia—Cisplatin—bone cancer	0.000934	0.00566	CcSEcCtD
Trabectedin—Extravasation—Epirubicin—bone cancer	0.000923	0.00559	CcSEcCtD
Trabectedin—Hyperbilirubinaemia—Epirubicin—bone cancer	0.000886	0.00536	CcSEcCtD
Trabectedin—Liver injury—Doxorubicin—bone cancer	0.000886	0.00536	CcSEcCtD
Trabectedin—Pulmonary embolism—Methotrexate—bone cancer	0.000861	0.00521	CcSEcCtD
Trabectedin—Stomatitis—Cisplatin—bone cancer	0.000855	0.00518	CcSEcCtD
Trabectedin—Extravasation—Doxorubicin—bone cancer	0.000854	0.00517	CcSEcCtD
Trabectedin—Hepatobiliary disease—Cisplatin—bone cancer	0.00083	0.00502	CcSEcCtD
Trabectedin—Hyperbilirubinaemia—Doxorubicin—bone cancer	0.000819	0.00496	CcSEcCtD
Trabectedin—Musculoskeletal pain—Epirubicin—bone cancer	0.000815	0.00494	CcSEcCtD
Trabectedin—Pulmonary embolism—Epirubicin—bone cancer	0.000805	0.00488	CcSEcCtD
Trabectedin—Injection site reaction—Epirubicin—bone cancer	0.000801	0.00485	CcSEcCtD
Trabectedin—Connective tissue disorder—Cisplatin—bone cancer	0.000774	0.00469	CcSEcCtD
Trabectedin—Pulmonary oedema—Methotrexate—bone cancer	0.000766	0.00464	CcSEcCtD
Trabectedin—Musculoskeletal pain—Doxorubicin—bone cancer	0.000754	0.00457	CcSEcCtD
Trabectedin—Sepsis—Methotrexate—bone cancer	0.000747	0.00452	CcSEcCtD
Trabectedin—Pulmonary embolism—Doxorubicin—bone cancer	0.000745	0.00451	CcSEcCtD
Trabectedin—Injection site reaction—Doxorubicin—bone cancer	0.000741	0.00449	CcSEcCtD
Trabectedin—Flushing—Cisplatin—bone cancer	0.000731	0.00443	CcSEcCtD
Trabectedin—Pulmonary oedema—Epirubicin—bone cancer	0.000717	0.00434	CcSEcCtD
Trabectedin—Mediastinal disorder—Cisplatin—bone cancer	0.00071	0.0043	CcSEcCtD
Trabectedin—Sepsis—Epirubicin—bone cancer	0.000699	0.00423	CcSEcCtD
Trabectedin—Alopecia—Cisplatin—bone cancer	0.000696	0.00421	CcSEcCtD
Trabectedin—Hepatic failure—Methotrexate—bone cancer	0.000695	0.00421	CcSEcCtD
Trabectedin—Malnutrition—Cisplatin—bone cancer	0.000686	0.00415	CcSEcCtD
Trabectedin—Blood alkaline phosphatase increased—Epirubicin—bone cancer	0.000672	0.00407	CcSEcCtD
Trabectedin—Pulmonary oedema—Doxorubicin—bone cancer	0.000663	0.00402	CcSEcCtD
Trabectedin—Hepatic failure—Epirubicin—bone cancer	0.00065	0.00394	CcSEcCtD
Trabectedin—Sepsis—Doxorubicin—bone cancer	0.000647	0.00392	CcSEcCtD
Trabectedin—Anaemia—Cisplatin—bone cancer	0.000634	0.00384	CcSEcCtD
Trabectedin—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.000622	0.00377	CcSEcCtD
Trabectedin—Leukopenia—Cisplatin—bone cancer	0.000614	0.00372	CcSEcCtD
Trabectedin—Hepatic failure—Doxorubicin—bone cancer	0.000602	0.00364	CcSEcCtD
Trabectedin—Myalgia—Cisplatin—bone cancer	0.000584	0.00353	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00058	0.00351	CcSEcCtD
Trabectedin—Oedema—Cisplatin—bone cancer	0.000559	0.00339	CcSEcCtD
Trabectedin—Infection—Cisplatin—bone cancer	0.000556	0.00337	CcSEcCtD
Trabectedin—Nervous system disorder—Cisplatin—bone cancer	0.000549	0.00332	CcSEcCtD
Trabectedin—Thrombocytopenia—Cisplatin—bone cancer	0.000548	0.00332	CcSEcCtD
Trabectedin—Blood creatinine increased—Epirubicin—bone cancer	0.000548	0.00332	CcSEcCtD
Trabectedin—Dehydration—Epirubicin—bone cancer	0.000544	0.00329	CcSEcCtD
Trabectedin—Skin disorder—Cisplatin—bone cancer	0.000543	0.00329	CcSEcCtD
Trabectedin—Abdominal pain upper—Epirubicin—bone cancer	0.000534	0.00323	CcSEcCtD
Trabectedin—Anorexia—Cisplatin—bone cancer	0.000533	0.00323	CcSEcCtD
Trabectedin—Hypokalaemia—Epirubicin—bone cancer	0.000532	0.00322	CcSEcCtD
Trabectedin—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000526	0.00319	CcSEcCtD
Trabectedin—Hypotension—Cisplatin—bone cancer	0.000523	0.00317	CcSEcCtD
Trabectedin—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000516	0.00312	CcSEcCtD
Trabectedin—Pancytopenia—Methotrexate—bone cancer	0.000513	0.0031	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00051	0.00309	CcSEcCtD
Trabectedin—Blood creatinine increased—Doxorubicin—bone cancer	0.000507	0.00307	CcSEcCtD
Trabectedin—Neutropenia—Methotrexate—bone cancer	0.000505	0.00306	CcSEcCtD
Trabectedin—Dehydration—Doxorubicin—bone cancer	0.000503	0.00305	CcSEcCtD
Trabectedin—Paraesthesia—Cisplatin—bone cancer	0.000502	0.00304	CcSEcCtD
Trabectedin—Dyspnoea—Cisplatin—bone cancer	0.000499	0.00302	CcSEcCtD
Trabectedin—Abdominal pain upper—Doxorubicin—bone cancer	0.000494	0.00299	CcSEcCtD
Trabectedin—Hypokalaemia—Doxorubicin—bone cancer	0.000492	0.00298	CcSEcCtD
Trabectedin—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000487	0.00295	CcSEcCtD
Trabectedin—Decreased appetite—Cisplatin—bone cancer	0.000486	0.00295	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Cisplatin—bone cancer	0.000483	0.00292	CcSEcCtD
Trabectedin—Infestation—Methotrexate—bone cancer	0.000481	0.00291	CcSEcCtD
Trabectedin—Infestation NOS—Methotrexate—bone cancer	0.000481	0.00291	CcSEcCtD
Trabectedin—Pancytopenia—Epirubicin—bone cancer	0.00048	0.00291	CcSEcCtD
Trabectedin—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000477	0.00289	CcSEcCtD
Trabectedin—Neutropenia—Epirubicin—bone cancer	0.000472	0.00286	CcSEcCtD
Trabectedin—Stomatitis—Methotrexate—bone cancer	0.000469	0.00284	CcSEcCtD
Trabectedin—Weight decreased—Epirubicin—bone cancer	0.000457	0.00277	CcSEcCtD
Trabectedin—Hepatobiliary disease—Methotrexate—bone cancer	0.000455	0.00276	CcSEcCtD
Trabectedin—Infestation—Epirubicin—bone cancer	0.00045	0.00273	CcSEcCtD
Trabectedin—Infestation NOS—Epirubicin—bone cancer	0.00045	0.00273	CcSEcCtD
Trabectedin—Agranulocytosis—Methotrexate—bone cancer	0.000449	0.00272	CcSEcCtD
Trabectedin—Pancytopenia—Doxorubicin—bone cancer	0.000444	0.00269	CcSEcCtD
Trabectedin—Body temperature increased—Cisplatin—bone cancer	0.000442	0.00268	CcSEcCtD
Trabectedin—Stomatitis—Epirubicin—bone cancer	0.000439	0.00266	CcSEcCtD
Trabectedin—Jaundice—Epirubicin—bone cancer	0.000439	0.00266	CcSEcCtD
Trabectedin—Neutropenia—Doxorubicin—bone cancer	0.000437	0.00265	CcSEcCtD
Trabectedin—Haemoglobin—Methotrexate—bone cancer	0.000434	0.00263	CcSEcCtD
Trabectedin—Haemorrhage—Methotrexate—bone cancer	0.000432	0.00262	CcSEcCtD
Trabectedin—Hepatobiliary disease—Epirubicin—bone cancer	0.000426	0.00258	CcSEcCtD
Trabectedin—Weight decreased—Doxorubicin—bone cancer	0.000423	0.00256	CcSEcCtD
Trabectedin—Agranulocytosis—Epirubicin—bone cancer	0.00042	0.00255	CcSEcCtD
Trabectedin—Infestation—Doxorubicin—bone cancer	0.000417	0.00252	CcSEcCtD
Trabectedin—Infestation NOS—Doxorubicin—bone cancer	0.000417	0.00252	CcSEcCtD
Trabectedin—Hypersensitivity—Cisplatin—bone cancer	0.000412	0.0025	CcSEcCtD
Trabectedin—Haemoglobin—Epirubicin—bone cancer	0.000406	0.00246	CcSEcCtD
Trabectedin—Stomatitis—Doxorubicin—bone cancer	0.000406	0.00246	CcSEcCtD
Trabectedin—Jaundice—Doxorubicin—bone cancer	0.000406	0.00246	CcSEcCtD
Trabectedin—Haemorrhage—Epirubicin—bone cancer	0.000404	0.00245	CcSEcCtD
Trabectedin—Asthenia—Cisplatin—bone cancer	0.000401	0.00243	CcSEcCtD
Trabectedin—Oedema peripheral—Epirubicin—bone cancer	0.000398	0.00241	CcSEcCtD
Trabectedin—Connective tissue disorder—Epirubicin—bone cancer	0.000397	0.00241	CcSEcCtD
Trabectedin—Hepatobiliary disease—Doxorubicin—bone cancer	0.000394	0.00239	CcSEcCtD
Trabectedin—Angiopathy—Methotrexate—bone cancer	0.000392	0.00237	CcSEcCtD
Trabectedin—Mediastinal disorder—Methotrexate—bone cancer	0.000389	0.00236	CcSEcCtD
Trabectedin—Agranulocytosis—Doxorubicin—bone cancer	0.000389	0.00236	CcSEcCtD
Trabectedin—Diarrhoea—Cisplatin—bone cancer	0.000383	0.00232	CcSEcCtD
Trabectedin—Alopecia—Methotrexate—bone cancer	0.000382	0.00231	CcSEcCtD
Trabectedin—Mental disorder—Methotrexate—bone cancer	0.000379	0.00229	CcSEcCtD
Trabectedin—Malnutrition—Methotrexate—bone cancer	0.000376	0.00228	CcSEcCtD
Trabectedin—Haemoglobin—Doxorubicin—bone cancer	0.000376	0.00228	CcSEcCtD
Trabectedin—Flushing—Epirubicin—bone cancer	0.000375	0.00227	CcSEcCtD
Trabectedin—Haemorrhage—Doxorubicin—bone cancer	0.000374	0.00227	CcSEcCtD
Trabectedin—Oedema peripheral—Doxorubicin—bone cancer	0.000369	0.00223	CcSEcCtD
Trabectedin—Dysgeusia—Methotrexate—bone cancer	0.000368	0.00223	CcSEcCtD
Trabectedin—Connective tissue disorder—Doxorubicin—bone cancer	0.000368	0.00223	CcSEcCtD
Trabectedin—Angiopathy—Epirubicin—bone cancer	0.000367	0.00222	CcSEcCtD
Trabectedin—Mediastinal disorder—Epirubicin—bone cancer	0.000364	0.00221	CcSEcCtD
Trabectedin—Back pain—Methotrexate—bone cancer	0.000364	0.0022	CcSEcCtD
Trabectedin—Alopecia—Epirubicin—bone cancer	0.000357	0.00216	CcSEcCtD
Trabectedin—Vomiting—Cisplatin—bone cancer	0.000356	0.00215	CcSEcCtD
Trabectedin—Mental disorder—Epirubicin—bone cancer	0.000354	0.00215	CcSEcCtD
Trabectedin—Rash—Cisplatin—bone cancer	0.000353	0.00214	CcSEcCtD
Trabectedin—Dermatitis—Cisplatin—bone cancer	0.000352	0.00213	CcSEcCtD
Trabectedin—Malnutrition—Epirubicin—bone cancer	0.000352	0.00213	CcSEcCtD
Trabectedin—Anaemia—Methotrexate—bone cancer	0.000348	0.00211	CcSEcCtD
Trabectedin—Flushing—Doxorubicin—bone cancer	0.000347	0.0021	CcSEcCtD
Trabectedin—Dysgeusia—Epirubicin—bone cancer	0.000345	0.00209	CcSEcCtD
Trabectedin—Back pain—Epirubicin—bone cancer	0.000341	0.00206	CcSEcCtD
Trabectedin—Angiopathy—Doxorubicin—bone cancer	0.000339	0.00206	CcSEcCtD
Trabectedin—Mediastinal disorder—Doxorubicin—bone cancer	0.000337	0.00204	CcSEcCtD
Trabectedin—Leukopenia—Methotrexate—bone cancer	0.000337	0.00204	CcSEcCtD
Trabectedin—Nausea—Cisplatin—bone cancer	0.000332	0.00201	CcSEcCtD
Trabectedin—Alopecia—Doxorubicin—bone cancer	0.000331	0.002	CcSEcCtD
Trabectedin—Cough—Methotrexate—bone cancer	0.000328	0.00199	CcSEcCtD
Trabectedin—Mental disorder—Doxorubicin—bone cancer	0.000328	0.00199	CcSEcCtD
Trabectedin—Malnutrition—Doxorubicin—bone cancer	0.000326	0.00197	CcSEcCtD
Trabectedin—Anaemia—Epirubicin—bone cancer	0.000325	0.00197	CcSEcCtD
Trabectedin—Myalgia—Methotrexate—bone cancer	0.00032	0.00194	CcSEcCtD
Trabectedin—Arthralgia—Methotrexate—bone cancer	0.00032	0.00194	CcSEcCtD
Trabectedin—Dysgeusia—Doxorubicin—bone cancer	0.000319	0.00193	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000318	0.00193	CcSEcCtD
Trabectedin—Syncope—Epirubicin—bone cancer	0.000316	0.00191	CcSEcCtD
Trabectedin—Leukopenia—Epirubicin—bone cancer	0.000315	0.00191	CcSEcCtD
Trabectedin—Back pain—Doxorubicin—bone cancer	0.000315	0.00191	CcSEcCtD
Trabectedin—Loss of consciousness—Epirubicin—bone cancer	0.000309	0.00187	CcSEcCtD
Trabectedin—Cough—Epirubicin—bone cancer	0.000307	0.00186	CcSEcCtD
Trabectedin—Infection—Methotrexate—bone cancer	0.000305	0.00185	CcSEcCtD
Trabectedin—Nervous system disorder—Methotrexate—bone cancer	0.000301	0.00182	CcSEcCtD
Trabectedin—Anaemia—Doxorubicin—bone cancer	0.000301	0.00182	CcSEcCtD
Trabectedin—Thrombocytopenia—Methotrexate—bone cancer	0.000301	0.00182	CcSEcCtD
Trabectedin—Myalgia—Epirubicin—bone cancer	0.0003	0.00181	CcSEcCtD
Trabectedin—Arthralgia—Epirubicin—bone cancer	0.0003	0.00181	CcSEcCtD
Trabectedin—Skin disorder—Methotrexate—bone cancer	0.000298	0.00181	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000298	0.0018	CcSEcCtD
Trabectedin—Anorexia—Methotrexate—bone cancer	0.000293	0.00177	CcSEcCtD
Trabectedin—Syncope—Doxorubicin—bone cancer	0.000292	0.00177	CcSEcCtD
Trabectedin—Leukopenia—Doxorubicin—bone cancer	0.000292	0.00177	CcSEcCtD
Trabectedin—Oedema—Epirubicin—bone cancer	0.000287	0.00174	CcSEcCtD
Trabectedin—Hypotension—Methotrexate—bone cancer	0.000287	0.00174	CcSEcCtD
Trabectedin—Loss of consciousness—Doxorubicin—bone cancer	0.000286	0.00173	CcSEcCtD
Trabectedin—Infection—Epirubicin—bone cancer	0.000285	0.00173	CcSEcCtD
Trabectedin—Cough—Doxorubicin—bone cancer	0.000284	0.00172	CcSEcCtD
Trabectedin—Shock—Epirubicin—bone cancer	0.000283	0.00171	CcSEcCtD
Trabectedin—Nervous system disorder—Epirubicin—bone cancer	0.000282	0.00171	CcSEcCtD
Trabectedin—Thrombocytopenia—Epirubicin—bone cancer	0.000281	0.0017	CcSEcCtD
Trabectedin—SRC—EGF/EGFR Signaling Pathway—ATF1—bone cancer	0.000281	0.0024	CbGpPWpGaD
Trabectedin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00028	0.00169	CcSEcCtD
Trabectedin—Skin disorder—Epirubicin—bone cancer	0.000279	0.00169	CcSEcCtD
Trabectedin—Insomnia—Methotrexate—bone cancer	0.000278	0.00168	CcSEcCtD
Trabectedin—Myalgia—Doxorubicin—bone cancer	0.000277	0.00168	CcSEcCtD
Trabectedin—Arthralgia—Doxorubicin—bone cancer	0.000277	0.00168	CcSEcCtD
Trabectedin—SRC—TGF-beta Signaling Pathway—TGFBR2—bone cancer	0.000276	0.00236	CbGpPWpGaD
Trabectedin—Paraesthesia—Methotrexate—bone cancer	0.000276	0.00167	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000275	0.00167	CcSEcCtD
Trabectedin—PTGS1—Biological oxidations—CYP3A4—bone cancer	0.000275	0.00235	CbGpPWpGaD
Trabectedin—SRC—Internalization of ErbB1—EGFR—bone cancer	0.000275	0.00235	CbGpPWpGaD
Trabectedin—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000274	0.00234	CbGpPWpGaD
Trabectedin—Anorexia—Epirubicin—bone cancer	0.000274	0.00166	CcSEcCtD
Trabectedin—Dyspnoea—Methotrexate—bone cancer	0.000274	0.00166	CcSEcCtD
Trabectedin—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000272	0.00232	CbGpPWpGaD
Trabectedin—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	0.000271	0.00232	CbGpPWpGaD
Trabectedin—Dyspepsia—Methotrexate—bone cancer	0.00027	0.00164	CcSEcCtD
Trabectedin—Hypotension—Epirubicin—bone cancer	0.000268	0.00163	CcSEcCtD
Trabectedin—SRC—Regulation of Androgen receptor activity—JUN—bone cancer	0.000268	0.00229	CbGpPWpGaD
Trabectedin—Decreased appetite—Methotrexate—bone cancer	0.000267	0.00162	CcSEcCtD
Trabectedin—Oedema—Doxorubicin—bone cancer	0.000266	0.00161	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Methotrexate—bone cancer	0.000265	0.00161	CcSEcCtD
Trabectedin—Fatigue—Methotrexate—bone cancer	0.000265	0.0016	CcSEcCtD
Trabectedin—Infection—Doxorubicin—bone cancer	0.000264	0.0016	CcSEcCtD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000264	0.00226	CbGpPWpGaD
Trabectedin—SRC—FGF signaling pathway—JUN—bone cancer	0.000264	0.00225	CbGpPWpGaD
Trabectedin—SRC—ErbB Signaling Pathway—JUN—bone cancer	0.000264	0.00225	CbGpPWpGaD
Trabectedin—SRC—Signaling events mediated by TCPTP—EGFR—bone cancer	0.000264	0.00225	CbGpPWpGaD
Trabectedin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000262	0.00159	CcSEcCtD
Trabectedin—Shock—Doxorubicin—bone cancer	0.000262	0.00158	CcSEcCtD
Trabectedin—Nervous system disorder—Doxorubicin—bone cancer	0.000261	0.00158	CcSEcCtD
Trabectedin—Thrombocytopenia—Doxorubicin—bone cancer	0.00026	0.00158	CcSEcCtD
Trabectedin—SRC—RANKL/RANK Signaling Pathway—JUN—bone cancer	0.00026	0.00222	CbGpPWpGaD
Trabectedin—Insomnia—Epirubicin—bone cancer	0.00026	0.00157	CcSEcCtD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—BRAF—bone cancer	0.000259	0.00222	CbGpPWpGaD
Trabectedin—Skin disorder—Doxorubicin—bone cancer	0.000258	0.00156	CcSEcCtD
Trabectedin—Paraesthesia—Epirubicin—bone cancer	0.000258	0.00156	CcSEcCtD
Trabectedin—SRC—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000258	0.0022	CbGpPWpGaD
Trabectedin—SRC—FGF signaling pathway—MMP9—bone cancer	0.000257	0.00219	CbGpPWpGaD
Trabectedin—Dyspnoea—Epirubicin—bone cancer	0.000256	0.00155	CcSEcCtD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—RB1—bone cancer	0.000255	0.00218	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—PLAU—bone cancer	0.000254	0.00217	CbGpPWpGaD
Trabectedin—SRC—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—EGFR—bone cancer	0.000253	0.00217	CbGpPWpGaD
Trabectedin—Anorexia—Doxorubicin—bone cancer	0.000253	0.00153	CcSEcCtD
Trabectedin—Dyspepsia—Epirubicin—bone cancer	0.000253	0.00153	CcSEcCtD
Trabectedin—Gastrointestinal pain—Methotrexate—bone cancer	0.000251	0.00152	CcSEcCtD
Trabectedin—Decreased appetite—Epirubicin—bone cancer	0.00025	0.00151	CcSEcCtD
Trabectedin—Hypotension—Doxorubicin—bone cancer	0.000248	0.0015	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Epirubicin—bone cancer	0.000248	0.0015	CcSEcCtD
Trabectedin—Fatigue—Epirubicin—bone cancer	0.000248	0.0015	CcSEcCtD
Trabectedin—Constipation—Epirubicin—bone cancer	0.000246	0.00149	CcSEcCtD
Trabectedin—Abdominal pain—Methotrexate—bone cancer	0.000243	0.00147	CcSEcCtD
Trabectedin—Body temperature increased—Methotrexate—bone cancer	0.000243	0.00147	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000242	0.00147	CcSEcCtD
Trabectedin—Insomnia—Doxorubicin—bone cancer	0.00024	0.00146	CcSEcCtD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.00024	0.00205	CbGpPWpGaD
Trabectedin—SRC—Signaling events mediated by focal adhesion kinase—JUN—bone cancer	0.000239	0.00204	CbGpPWpGaD
Trabectedin—Paraesthesia—Doxorubicin—bone cancer	0.000239	0.00145	CcSEcCtD
Trabectedin—SRC—Androgen receptor signaling pathway—RB1—bone cancer	0.000239	0.00204	CbGpPWpGaD
Trabectedin—Dyspnoea—Doxorubicin—bone cancer	0.000237	0.00144	CcSEcCtD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000237	0.00203	CbGpPWpGaD
Trabectedin—SRC—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000236	0.00202	CbGpPWpGaD
Trabectedin—SRC—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000236	0.00201	CbGpPWpGaD
Trabectedin—SRC—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000236	0.00201	CbGpPWpGaD
Trabectedin—Gastrointestinal pain—Epirubicin—bone cancer	0.000235	0.00142	CcSEcCtD
Trabectedin—PTGS1—Biological oxidations—GSTP1—bone cancer	0.000235	0.00201	CbGpPWpGaD
Trabectedin—Dyspepsia—Doxorubicin—bone cancer	0.000234	0.00142	CcSEcCtD
Trabectedin—SRC—Endothelins—JUN—bone cancer	0.000233	0.00199	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—ATF1—bone cancer	0.000232	0.00198	CbGpPWpGaD
Trabectedin—SRC—GAB1 signalosome—KIT—bone cancer	0.000232	0.00198	CbGpPWpGaD
Trabectedin—Decreased appetite—Doxorubicin—bone cancer	0.000231	0.0014	CcSEcCtD
Trabectedin—SRC—LPA receptor mediated events—JUN—bone cancer	0.00023	0.00197	CbGpPWpGaD
Trabectedin—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00023	0.00139	CcSEcCtD
Trabectedin—Fatigue—Doxorubicin—bone cancer	0.000229	0.00139	CcSEcCtD
Trabectedin—SRC—Posttranslational regulation of adherens junction stability and dissassembly—EGFR—bone cancer	0.000228	0.00195	CbGpPWpGaD
Trabectedin—Constipation—Doxorubicin—bone cancer	0.000227	0.00138	CcSEcCtD
Trabectedin—Abdominal pain—Epirubicin—bone cancer	0.000227	0.00138	CcSEcCtD
Trabectedin—Body temperature increased—Epirubicin—bone cancer	0.000227	0.00138	CcSEcCtD
Trabectedin—Hypersensitivity—Methotrexate—bone cancer	0.000226	0.00137	CcSEcCtD
Trabectedin—SRC—TSH signaling pathway—JUN—bone cancer	0.000225	0.00192	CbGpPWpGaD
Trabectedin—SRC—AGE/RAGE pathway—JUN—bone cancer	0.000225	0.00192	CbGpPWpGaD
Trabectedin—SRC—LPA receptor mediated events—MMP9—bone cancer	0.000224	0.00191	CbGpPWpGaD
Trabectedin—SRC—Integrin-mediated Cell Adhesion—BRAF—bone cancer	0.000221	0.00189	CbGpPWpGaD
Trabectedin—Asthenia—Methotrexate—bone cancer	0.00022	0.00133	CcSEcCtD
Trabectedin—SRC—EPH-Ephrin signaling—MMP2—bone cancer	0.000219	0.00187	CbGpPWpGaD
Trabectedin—SRC—AGE/RAGE pathway—MMP9—bone cancer	0.000219	0.00187	CbGpPWpGaD
Trabectedin—Gastrointestinal pain—Doxorubicin—bone cancer	0.000217	0.00132	CcSEcCtD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—MDM2—bone cancer	0.000217	0.00186	CbGpPWpGaD
Trabectedin—SRC—CDC42 signaling events—JUN—bone cancer	0.000214	0.00183	CbGpPWpGaD
Trabectedin—SRC—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000214	0.00183	CbGpPWpGaD
Trabectedin—SRC—Signaling events mediated by PTP1B—EGFR—bone cancer	0.000214	0.00183	CbGpPWpGaD
Trabectedin—SRC—ErbB1 downstream signaling—BRAF—bone cancer	0.000213	0.00182	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—BRAF—bone cancer	0.000213	0.00182	CbGpPWpGaD
Trabectedin—Hypersensitivity—Epirubicin—bone cancer	0.000212	0.00128	CcSEcCtD
Trabectedin—Body temperature increased—Doxorubicin—bone cancer	0.00021	0.00127	CcSEcCtD
Trabectedin—Abdominal pain—Doxorubicin—bone cancer	0.00021	0.00127	CcSEcCtD
Trabectedin—Diarrhoea—Methotrexate—bone cancer	0.00021	0.00127	CcSEcCtD
Trabectedin—SRC—Senescence and Autophagy in Cancer—RB1—bone cancer	0.000209	0.00179	CbGpPWpGaD
Trabectedin—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	0.000208	0.00178	CbGpPWpGaD
Trabectedin—SRC—ErbB Signaling Pathway—EGFR—bone cancer	0.000207	0.00177	CbGpPWpGaD
Trabectedin—Asthenia—Epirubicin—bone cancer	0.000206	0.00125	CcSEcCtD
Trabectedin—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.000205	0.00175	CbGpPWpGaD
Trabectedin—SRC—Androgen receptor signaling pathway—MDM2—bone cancer	0.000203	0.00174	CbGpPWpGaD
Trabectedin—Dizziness—Methotrexate—bone cancer	0.000203	0.00123	CcSEcCtD
Trabectedin—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.000202	0.00173	CbGpPWpGaD
Trabectedin—SRC—Thromboxane A2 receptor signaling—EGFR—bone cancer	0.000201	0.00172	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000201	0.00172	CbGpPWpGaD
Trabectedin—SRC—TGF-beta Signaling Pathway—MET—bone cancer	0.0002	0.00171	CbGpPWpGaD
Trabectedin—Diarrhoea—Epirubicin—bone cancer	0.000197	0.00119	CcSEcCtD
Trabectedin—Hypersensitivity—Doxorubicin—bone cancer	0.000196	0.00119	CcSEcCtD
Trabectedin—Vomiting—Methotrexate—bone cancer	0.000195	0.00118	CcSEcCtD
Trabectedin—SRC—Focal Adhesion—IGF1R—bone cancer	0.000194	0.00166	CbGpPWpGaD
Trabectedin—Rash—Methotrexate—bone cancer	0.000194	0.00117	CcSEcCtD
Trabectedin—Dermatitis—Methotrexate—bone cancer	0.000193	0.00117	CcSEcCtD
Trabectedin—SRC—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—JUN—bone cancer	0.000193	0.00165	CbGpPWpGaD
Trabectedin—Headache—Methotrexate—bone cancer	0.000192	0.00116	CcSEcCtD
Trabectedin—Asthenia—Doxorubicin—bone cancer	0.000191	0.00116	CcSEcCtD
Trabectedin—Dizziness—Epirubicin—bone cancer	0.00019	0.00115	CcSEcCtD
Trabectedin—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000189	0.00161	CbGpPWpGaD
Trabectedin—SRC—PDGFR-beta signaling pathway—BRAF—bone cancer	0.000185	0.00158	CbGpPWpGaD
Trabectedin—Vomiting—Epirubicin—bone cancer	0.000183	0.00111	CcSEcCtD
Trabectedin—SRC—GAB1 signalosome—MDM2—bone cancer	0.000182	0.00156	CbGpPWpGaD
Trabectedin—Nausea—Methotrexate—bone cancer	0.000182	0.0011	CcSEcCtD
Trabectedin—Diarrhoea—Doxorubicin—bone cancer	0.000182	0.0011	CcSEcCtD
Trabectedin—Rash—Epirubicin—bone cancer	0.000181	0.0011	CcSEcCtD
Trabectedin—Dermatitis—Epirubicin—bone cancer	0.000181	0.0011	CcSEcCtD
Trabectedin—SRC—LPA receptor mediated events—EGFR—bone cancer	0.000181	0.00155	CbGpPWpGaD
Trabectedin—SRC—CXCR4-mediated signaling events—MMP9—bone cancer	0.00018	0.00154	CbGpPWpGaD
Trabectedin—Headache—Epirubicin—bone cancer	0.00018	0.00109	CcSEcCtD
Trabectedin—SRC—Signaling by SCF-KIT—KIT—bone cancer	0.000179	0.00153	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—ATF1—bone cancer	0.000178	0.00152	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—MDM2—bone cancer	0.000178	0.00152	CbGpPWpGaD
Trabectedin—SRC—Androgen receptor signaling pathway—JUN—bone cancer	0.000177	0.00151	CbGpPWpGaD
Trabectedin—SRC—AGE/RAGE pathway—EGFR—bone cancer	0.000177	0.00151	CbGpPWpGaD
Trabectedin—Dizziness—Doxorubicin—bone cancer	0.000176	0.00106	CcSEcCtD
Trabectedin—CYP2E1—Biological oxidations—GSTP1—bone cancer	0.000176	0.0015	CbGpPWpGaD
Trabectedin—SRC—Rac1/Pak1/p38/MMP-2 pathway—EGFR—bone cancer	0.000174	0.00149	CbGpPWpGaD
Trabectedin—SRC—ErbB Signaling Pathway—TP53—bone cancer	0.000174	0.00149	CbGpPWpGaD
Trabectedin—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	0.000173	0.00148	CbGpPWpGaD
Trabectedin—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000172	0.00147	CbGpPWpGaD
Trabectedin—Nausea—Epirubicin—bone cancer	0.000171	0.00103	CcSEcCtD
Trabectedin—Vomiting—Doxorubicin—bone cancer	0.000169	0.00102	CcSEcCtD
Trabectedin—Rash—Doxorubicin—bone cancer	0.000168	0.00102	CcSEcCtD
Trabectedin—Dermatitis—Doxorubicin—bone cancer	0.000167	0.00101	CcSEcCtD
Trabectedin—Headache—Doxorubicin—bone cancer	0.000167	0.00101	CcSEcCtD
Trabectedin—SRC—EPH-Ephrin signaling—MMP9—bone cancer	0.000165	0.00141	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—NDUFA12—bone cancer	0.000165	0.00141	CbGpPWpGaD
Trabectedin—SRC—Downstream signal transduction—KIT—bone cancer	0.000161	0.00137	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR—KIT—bone cancer	0.00016	0.00137	CbGpPWpGaD
Trabectedin—SRC—Signaling by ERBB2—KIT—bone cancer	0.000159	0.00136	CbGpPWpGaD
Trabectedin—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000158	0.00135	CbGpPWpGaD
Trabectedin—Nausea—Doxorubicin—bone cancer	0.000158	0.000956	CcSEcCtD
Trabectedin—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000156	0.00134	CbGpPWpGaD
Trabectedin—SRC—ErbB1 downstream signaling—JUN—bone cancer	0.000155	0.00132	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—JUN—bone cancer	0.000155	0.00132	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR—BRAF—bone cancer	0.00015	0.00129	CbGpPWpGaD
Trabectedin—SRC—EGF/EGFR Signaling Pathway—BRAF—bone cancer	0.00015	0.00129	CbGpPWpGaD
Trabectedin—SRC—Oncostatin M Signaling Pathway—TP53—bone cancer	0.00015	0.00128	CbGpPWpGaD
Trabectedin—SRC—Focal Adhesion—MET—bone cancer	0.00015	0.00128	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR in disease—KIT—bone cancer	0.000149	0.00127	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000149	0.00127	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—EGFR—bone cancer	0.000148	0.00127	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR—KIT—bone cancer	0.000148	0.00126	CbGpPWpGaD
Trabectedin—SRC—Rac1/Pak1/p38/MMP-2 pathway—TP53—bone cancer	0.000146	0.00125	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR in Cancer—KIT—bone cancer	0.000146	0.00125	CbGpPWpGaD
Trabectedin—SRC—Signaling by PDGF—KIT—bone cancer	0.000146	0.00125	CbGpPWpGaD
Trabectedin—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000146	0.00125	CbGpPWpGaD
Trabectedin—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000144	0.00123	CbGpPWpGaD
Trabectedin—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000144	0.00123	CbGpPWpGaD
Trabectedin—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000142	0.00122	CbGpPWpGaD
Trabectedin—SRC—Signaling by SCF-KIT—MDM2—bone cancer	0.000141	0.0012	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR in disease—BRAF—bone cancer	0.00014	0.0012	CbGpPWpGaD
Trabectedin—SRC—Androgen receptor signaling pathway—EGFR—bone cancer	0.000139	0.00119	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—NT5C3A—bone cancer	0.000136	0.00117	CbGpPWpGaD
Trabectedin—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000135	0.00116	CbGpPWpGaD
Trabectedin—SRC—PDGFR-beta signaling pathway—JUN—bone cancer	0.000135	0.00115	CbGpPWpGaD
Trabectedin—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.000134	0.00114	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—SPARC—bone cancer	0.000133	0.00114	CbGpPWpGaD
Trabectedin—SRC—Focal Adhesion—BRAF—bone cancer	0.000132	0.00113	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	0.000132	0.00113	CbGpPWpGaD
Trabectedin—SRC—L1CAM interactions—EGFR—bone cancer	0.000131	0.00112	CbGpPWpGaD
Trabectedin—SRC—TGF-beta Signaling Pathway—JUN—bone cancer	0.000129	0.0011	CbGpPWpGaD
Trabectedin—SRC—Downstream signal transduction—MDM2—bone cancer	0.000127	0.00108	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR—MDM2—bone cancer	0.000126	0.00108	CbGpPWpGaD
Trabectedin—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000126	0.00107	CbGpPWpGaD
Trabectedin—SRC—Signaling by ERBB2—MDM2—bone cancer	0.000125	0.00107	CbGpPWpGaD
Trabectedin—SRC—GAB1 signalosome—EGFR—bone cancer	0.000125	0.00107	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways in Glioblastoma—TP53—bone cancer	0.000125	0.00107	CbGpPWpGaD
Trabectedin—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000125	0.00106	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	0.000124	0.00106	CbGpPWpGaD
Trabectedin—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000124	0.00106	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—NDUFA12—bone cancer	0.000123	0.00105	CbGpPWpGaD
Trabectedin—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000123	0.00105	CbGpPWpGaD
Trabectedin—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000122	0.00104	CbGpPWpGaD
Trabectedin—SRC—ErbB1 downstream signaling—EGFR—bone cancer	0.000122	0.00104	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—GNA11—bone cancer	0.000122	0.00104	CbGpPWpGaD
Trabectedin—SRC—BDNF signaling pathway—JUN—bone cancer	0.00012	0.00103	CbGpPWpGaD
Trabectedin—SRC—Signaling by SCF-KIT—MMP9—bone cancer	0.000119	0.00102	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR in disease—MDM2—bone cancer	0.000117	0.001	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR—MDM2—bone cancer	0.000116	0.000994	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR in Cancer—MDM2—bone cancer	0.000115	0.000985	CbGpPWpGaD
Trabectedin—SRC—Signaling by PDGF—MDM2—bone cancer	0.000115	0.000981	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.00011	0.000944	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—IL3—bone cancer	0.00011	0.000942	CbGpPWpGaD
Trabectedin—SRC—EGF/EGFR Signaling Pathway—JUN—bone cancer	0.00011	0.000936	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000106	0.00091	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	0.000104	0.000889	CbGpPWpGaD
Trabectedin—SRC—Senescence and Autophagy in Cancer—TP53—bone cancer	0.000102	0.000874	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—NT5C3A—bone cancer	0.000102	0.000871	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—ATF1—bone cancer	0.000102	0.00087	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—KIT—bone cancer	0.000102	0.000868	CbGpPWpGaD
Trabectedin—SRC—Axon guidance—MET—bone cancer	9.76e-05	0.000834	CbGpPWpGaD
Trabectedin—SRC—Focal Adhesion—JUN—bone cancer	9.64e-05	0.000824	CbGpPWpGaD
Trabectedin—SRC—Signaling by SCF-KIT—EGFR—bone cancer	9.62e-05	0.000822	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	9.6e-05	0.00082	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—BRAF—bone cancer	9.54e-05	0.000816	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—NDUFA12—bone cancer	9.49e-05	0.000811	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—NDUFA12—bone cancer	8.73e-05	0.000746	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—NDUFA12—bone cancer	8.66e-05	0.00074	CbGpPWpGaD
Trabectedin—SRC—Downstream signal transduction—EGFR—bone cancer	8.65e-05	0.00074	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR—EGFR—bone cancer	8.61e-05	0.000736	CbGpPWpGaD
Trabectedin—SRC—EGF/EGFR Signaling Pathway—EGFR—bone cancer	8.61e-05	0.000736	CbGpPWpGaD
Trabectedin—SRC—Signaling by ERBB2—EGFR—bone cancer	8.57e-05	0.000732	CbGpPWpGaD
Trabectedin—SRC—TGF-beta Signaling Pathway—TP53—bone cancer	8.52e-05	0.000728	CbGpPWpGaD
Trabectedin—CYP3A4—Biological oxidations—GSTP1—bone cancer	8.15e-05	0.000696	CbGpPWpGaD
Trabectedin—SRC—Axon guidance—MMP2—bone cancer	8.14e-05	0.000696	CbGpPWpGaD
Trabectedin—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	8.03e-05	0.000687	CbGpPWpGaD
Trabectedin—SRC—Signaling by FGFR in disease—EGFR—bone cancer	8.02e-05	0.000686	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—MDM2—bone cancer	7.99e-05	0.000683	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR—EGFR—bone cancer	7.95e-05	0.000679	CbGpPWpGaD
Trabectedin—SRC—Signaling by EGFR in Cancer—EGFR—bone cancer	7.88e-05	0.000673	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—NT5C3A—bone cancer	7.87e-05	0.000672	CbGpPWpGaD
Trabectedin—SRC—Signaling by PDGF—EGFR—bone cancer	7.84e-05	0.00067	CbGpPWpGaD
Trabectedin—SRC—Focal Adhesion—EGFR—bone cancer	7.58e-05	0.000648	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	7.55e-05	0.000645	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—GRM4—bone cancer	7.38e-05	0.00063	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—RGS1—bone cancer	7.38e-05	0.00063	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—NT5C3A—bone cancer	7.23e-05	0.000618	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—PLAU—bone cancer	7.23e-05	0.000618	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—NT5C3A—bone cancer	7.17e-05	0.000613	CbGpPWpGaD
Trabectedin—SRC—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	7.1e-05	0.000607	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—MET—bone cancer	6.96e-05	0.000595	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—CDK4—bone cancer	6.96e-05	0.000595	CbGpPWpGaD
Trabectedin—SRC—Disease—ENO2—bone cancer	6.79e-05	0.00058	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—GRM1—bone cancer	6.4e-05	0.000547	CbGpPWpGaD
Trabectedin—SRC—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	6.34e-05	0.000542	CbGpPWpGaD
Trabectedin—SRC—Disease—DHFR—bone cancer	6.3e-05	0.000538	CbGpPWpGaD
Trabectedin—SRC—Axon guidance—MMP9—bone cancer	6.12e-05	0.000523	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—ENO2—bone cancer	5.98e-05	0.000511	CbGpPWpGaD
Trabectedin—SRC—Immune System—ATF1—bone cancer	5.93e-05	0.000506	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—MMP2—bone cancer	5.81e-05	0.000497	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—KIT—bone cancer	5.79e-05	0.000495	CbGpPWpGaD
Trabectedin—SRC—Immune System—IL3—bone cancer	5.78e-05	0.000494	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—NDUFA12—bone cancer	5.71e-05	0.000488	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—KIT—bone cancer	5.56e-05	0.000475	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—DHFR—bone cancer	5.54e-05	0.000474	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—EGFR—bone cancer	5.46e-05	0.000467	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—GNA11—bone cancer	5.18e-05	0.000443	CbGpPWpGaD
Trabectedin—SRC—Axon guidance—EGFR—bone cancer	4.94e-05	0.000423	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—NT5C3A—bone cancer	4.73e-05	0.000404	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—CYP3A4—bone cancer	4.7e-05	0.000402	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.67e-05	0.000399	CbGpPWpGaD
Trabectedin—SRC—Disease—TGFBR2—bone cancer	4.56e-05	0.00039	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—MDM2—bone cancer	4.56e-05	0.00039	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—SMO—bone cancer	4.51e-05	0.000385	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—ENO2—bone cancer	4.47e-05	0.000382	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—MDM2—bone cancer	4.38e-05	0.000374	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—MMP9—bone cancer	4.37e-05	0.000373	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—DHFR—bone cancer	4.14e-05	0.000354	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—GNA11—bone cancer	4.12e-05	0.000352	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—GSTP1—bone cancer	4.02e-05	0.000343	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—JUN—bone cancer	3.96e-05	0.000339	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—GNA11—bone cancer	3.87e-05	0.000331	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—ATF1—bone cancer	3.83e-05	0.000327	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—IL3—bone cancer	3.74e-05	0.000319	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—EGFR—bone cancer	3.53e-05	0.000302	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—CYP3A4—bone cancer	3.51e-05	0.0003	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—ENO2—bone cancer	3.45e-05	0.000295	CbGpPWpGaD
Trabectedin—SRC—Immune System—KIT—bone cancer	3.37e-05	0.000288	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—DHFR—bone cancer	3.2e-05	0.000273	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—TGFBR2—bone cancer	3.2e-05	0.000273	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—ENO2—bone cancer	3.17e-05	0.000271	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—ENO2—bone cancer	3.14e-05	0.000269	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—EGFR—bone cancer	3.12e-05	0.000266	CbGpPWpGaD
Trabectedin—SRC—Disease—KIT—bone cancer	3.11e-05	0.000266	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—IGF1R—bone cancer	3.01e-05	0.000257	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—GSTP1—bone cancer	3e-05	0.000257	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—EGFR—bone cancer	2.99e-05	0.000256	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—GNA11—bone cancer	2.99e-05	0.000255	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—DHFR—bone cancer	2.94e-05	0.000251	CbGpPWpGaD
Trabectedin—SRC—Disease—BRAF—bone cancer	2.93e-05	0.00025	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—DHFR—bone cancer	2.91e-05	0.000249	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—TP53—bone cancer	2.91e-05	0.000248	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—GNA11—bone cancer	2.75e-05	0.000235	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—GNA11—bone cancer	2.72e-05	0.000233	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—CYP3A4—bone cancer	2.71e-05	0.000231	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.69e-05	0.00023	CbGpPWpGaD
Trabectedin—SRC—Immune System—MDM2—bone cancer	2.66e-05	0.000227	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—CYP3A4—bone cancer	2.49e-05	0.000213	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—CYP3A4—bone cancer	2.47e-05	0.000211	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.46e-05	0.00021	CbGpPWpGaD
Trabectedin—SRC—Disease—MDM2—bone cancer	2.45e-05	0.00021	CbGpPWpGaD
Trabectedin—SRC—Disease—PTGS2—bone cancer	2.36e-05	0.000202	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—GSTP1—bone cancer	2.32e-05	0.000198	CbGpPWpGaD
Trabectedin—SRC—Immune System—JUN—bone cancer	2.31e-05	0.000197	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—KIT—bone cancer	2.18e-05	0.000186	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—GSTP1—bone cancer	2.13e-05	0.000182	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—GSTP1—bone cancer	2.11e-05	0.000181	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—PTGS2—bone cancer	2.08e-05	0.000178	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—ENO2—bone cancer	2.07e-05	0.000177	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—BRAF—bone cancer	2.05e-05	0.000175	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—DHFR—bone cancer	1.92e-05	0.000164	CbGpPWpGaD
Trabectedin—SRC—Immune System—EGFR—bone cancer	1.82e-05	0.000155	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—GNA11—bone cancer	1.8e-05	0.000154	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—MDM2—bone cancer	1.72e-05	0.000147	CbGpPWpGaD
Trabectedin—SRC—Disease—EGFR—bone cancer	1.68e-05	0.000143	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—PTGS2—bone cancer	1.56e-05	0.000133	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—JUN—bone cancer	1.49e-05	0.000128	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—MMP9—bone cancer	1.45e-05	0.000124	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—GSTP1—bone cancer	1.39e-05	0.000119	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—PTGS2—bone cancer	1.2e-05	0.000103	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—EGFR—bone cancer	1.17e-05	0.0001	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—PTGS2—bone cancer	1.1e-05	9.43e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—PTGS2—bone cancer	1.09e-05	9.35e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—TP53—bone cancer	9.85e-06	8.42e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—PTGS2—bone cancer	7.22e-06	6.17e-05	CbGpPWpGaD
